t-PA mutants F305H; F305H; A292S alone or in combination with R275E for the treatment of stroke because they show a significantly reduced neurotoxicity due to their increased fibrin specificity compared with wild type t-PA

摘要

Disclosed is the use of a plasminogen activating factor for the manufacture of a medicament for the treatment of stroke in a human at least 3 hours after onset of the stroke, wherein the plasminogen activating factor does not exhibit a neurodegenerative effect of wild type t-PA, and the plasminogen activating factor is not Desmodus rotundus salivary plasminogen activator (DSPA).